Otsuka Acquires Cantargia’s CAN10 IL1RAP Antibody Immunology Program
Cantargia AB has announced a landmark agreement with Japanese pharma giant Otsuka Pharmaceutical Co., Ltd., granting Otsuka exclusive global rights
Read moreCantargia AB has announced a landmark agreement with Japanese pharma giant Otsuka Pharmaceutical Co., Ltd., granting Otsuka exclusive global rights
Read moreRetinal degeneration represents a primary cause of irreversible blindness, with both its onset and severity differing significantly among various conditions.
Read moreStriatech, a leader in preclinical vision research devices and tools, has unveiled its New Non-Aversive Animal Platform for the OptoDrum
Read moreA groundbreaking study by Groh et al., recently featured in Nature Communications, delves into the interplay between adaptive immunity and
Read moreCutting-edge CacoReady Cell-based Plates with pre-developed Caco-2 cells for in vitro permeability assessment have been a key tool in a
Read moreChoosing the most appropriate well system format, whether it’s a transwell, non-transwell, or individual transwell, can drastically affect the outcome
Read moreThe unique rapid plasma protein binding assay for sticky and tightly bound compounds can be used with plasma from any
Read moreThe Ksander Lab at Boston’s Schepens Eye Research Institute has unveiled valuable insights into the role of subretinal microglia in
Read moreMillions of individuals worldwide are affected by vision loss caused by retinal degenerative diseases, such as retinitis pigmentosa (RP) and
Read moreIn vitro mammalian cells such as Caco-2 or MDCKII, crucial for preclinical research and drug discovery, are highly challenging to
Read more